A study on the expression of Her2/neu in malignant epithelial ovarian tumors
Background: Ovarian cancer poses a considerable challenge in surgical treatment, often requiring careful and complex approaches. A review of the literature highlights a wide range of Her2/neu overexpression or amplifications in ovarian tumors, with reported rates between 8% and 66%. This variability...
Saved in:
Main Authors: | Amit Kumar Bhardwaj, Vanita Bhaskar, Rashmi Nayak, Anubhav Chandrakar, Vikas Bombeshwar, Vikas Kailashiya |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | MGM Journal of Medical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.4103/mgmj.mgmj_235_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis
by: Emily J. Tomas, et al.
Published: (2025-01-01) -
Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma
by: Kristina Mae Bienes, et al.
Published: (2025-01-01) -
Disease-free survival of 15 years after primary surgery in a patient with advanced high-grade serous ovarian cancer: a case report and literature review
by: Yaoqi Shi, et al.
Published: (2025-01-01) -
Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation
by: Aline Talhouk, et al.
Published: (2025-01-01) -
Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures
by: Mariana Nunes, et al.
Published: (2024-12-01)